

Dear Manufacturers,

I am writing on behalf of Immanuel Medical Center (DSH280081) to inform manufacturers that Immanuel Medical Center recently underwent an audit by the Health Resources and Services Administration (HRSA) of Immanuel Medical Center's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Immanuel Medical Center qualified for the 340B Program as a Disproportionate Share Hospital in Omaha, Nebraska and has participated in the 340B Program since April 1, 2005.

Through the audit process, Immanuel Medical Center was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following finding(s):

Finding 1 - Dispensing 340B drugs to ineligible individuals as prohibited by 42 USC 256b(a)(5)(B).

Finding 2 – Billing Medicaid contrary to the information contained in the HRSA Medicaid Exclusion File. This action may have resulted in duplicate discounts as prohibited by 42 USC 256(a)(5)(A).

Immanuel Medical Center has identified all affected manufacturers and has contacted each through certified mail to notify them of these areas of non-compliance to begin a dialogue on a method for repayment to affected manufacturers. If you have any questions or comments regarding the violations described in this letter please contact Gregory Breiling at (402) 572-3026 or at Immanuel Medical Center – Pharmacy Dept, 6901 N 72<sup>nd</sup> Street, Omaha, NE 68122.

Sincerely,

/s/

Tim Schnack  
Alegent Creighton Health  
Immanuel Medical Center  
CFO Immanuel Medical Center